Join the Lamictal group to help and get support from people like you.
Lamictal News
Autism Risk May Rise With In Utero Exposure to Antiseizure Meds
WEDNESDAY, March 20, 2024 – The incidence of autism spectrum disorder is higher among children exposed to topiramate in the second half of pregnancy compared with the general population of children...
Prenatal Valproate Exposure Tied to Psychiatric Disorders in Late Childhood
WEDNESDAY, May 24, 2023 – Prenatal exposure to the antiepileptic medication valproate is associated with an increased risk for later psychiatric disorders among children of mothers with epilepsy,...
FDA Medwatch Alert: Drug Safety Communication: Lamictal (lamotrigine) - Studies Show Increased Risk of Heart Rhythm Problems in Patients with Heart Disease
March 31, 2021 – A U.S. Food and Drug Administration (FDA) review of study findings showed a potential increased risk of heart rhythm problems, called arrhythmias, in patients with heart disease who...
FDA Medwatch Alert: Taro Pharmaceuticals U.S.A., Inc. Issues Voluntary Nationwide Recall of Lamotrigine Tablets USP, 100 mg, 100 Count Bottles
January 10, 2020 – Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling one (1) lot of Lamotrigine 100 mg Tablets, Lot # 331771 (expiration date June 2021) in 100 coun...
FDA Medwatch Alert: Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction
ISSUE: The FDA is warning that the medicine Lamictal (lamotrigine) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s i...
FDA Medwatch Alert: Lamotrigine Orally Disintegrating Tablet 200 mg by Impax: Recall - Incorrect Labeling of Blister Cards
ISSUE: Impax Laboratories, Inc. issued a voluntary nationwide retail level recall on August 19, 2016 for one lot of Lamotrigine Orally Disintegrating Tablet (ODT) 200 mg, NDC 0115-1529-08, Lot #...
FDA Approves Lamictal XR (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
RESEARCH TRIANGLE PARK, N.C., April 25, 2011 /PRNewswire/ – GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved Lamictal XR (lamotrigine)...
FDA Approves Once-A-Day Lamictal XR as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures
RESEARCH TRIANGLE PARK, N.C., Jan. 29 /PRNewswire-FirstCall/ – GlaxoSmithKline announced today that the U.S. Food and Drug Administration has approved Lamictal XR (lamotrigine) Extended-Release...
FDA Medwatch Alert: Lamictal (lamotrigine)
[Posted 09/29/2006] The FDA notified healthcare professionals and patients of new preliminary information from the North American Antiepileptic Drug Pregnancy Registry that suggests that babies...
FDA Medwatch Alert: Antiepileptic Drugs
[UPDATE 05/05/2009] FDA notified healthcare professionals that it approved updated labeling for antiepileptic drugs used to treat epilepsy, psychiatric disorders, and other conditions (e.g., migraine...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Bipolar Disorder, Lennox-Gastaut Syndrome, Epilepsy, Seizure Prevention, Seizure Prophylaxis